Philadelphia chromosome-positive leukemia
GPTKB entity
Statements (54)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Oncology
|
gptkbp:affects |
blood cells
|
gptkbp:associated_with |
gptkb:anemia
gptkb:BCR-ABL_fusion_gene thrombocytopenia poor prognosis increased white blood cell count |
gptkbp:can_be_used_to |
night sweats
lymphadenopathy pallor |
gptkbp:can_cause |
hepatomegaly
splenomegaly |
gptkbp:can_detect |
cytogenetic analysis
FISH analysis |
gptkbp:can_lead_to |
gptkb:chronic_myeloid_leukemia
gptkb:Oncology blast crisis |
gptkbp:clinical_trial |
ongoing research
|
gptkbp:diagnosis |
bone marrow biopsy
|
gptkbp:duration |
long-term therapy
|
gptkbp:first_described_by |
1960s
|
gptkbp:genetic_studies |
gptkb:BCR-ABL1
|
gptkbp:has_achieved |
infections
bleeding disorders |
gptkbp:has_chromosome |
gptkb:Philadelphia_chromosome
|
https://www.w3.org/2000/01/rdf-schema#label |
Philadelphia chromosome-positive leukemia
|
gptkbp:is_associated_with |
CML
ALL |
gptkbp:is_characterized_by |
chromosomal translocation
abnormal cell proliferation |
gptkbp:is_common_in |
gptkb:children
adults men |
gptkbp:is_considered |
a type of cancer
|
gptkbp:is_linked_to |
poor response to standard chemotherapy
|
gptkbp:is_monitored_by |
PCR testing
|
gptkbp:is_studied_in |
clinical research
|
gptkbp:prevalence |
approximately 15-30% of adult acute lymphoblastic leukemia cases
|
gptkbp:requires |
regular monitoring
stem cell transplant |
gptkbp:risk_factor |
exposure to radiation
certain genetic disorders |
gptkbp:symptoms |
fatigue
weight loss fever |
gptkbp:treatment |
gptkb:imatinib
gptkb:dasatinib gptkb:nilotinib tyrosine kinase inhibitors remission hematologist eradication of leukemic cells |
gptkbp:bfsParent |
gptkb:Gleevec
|
gptkbp:bfsLayer |
5
|